Search

Your search keyword '"Han, J-Y."' showing total 2,652 results

Search Constraints

Start Over You searched for: Author "Han, J-Y." Remove constraint Author: "Han, J-Y."
2,652 results on '"Han, J-Y."'

Search Results

101. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

108. PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L

109. High-precision measurement of the W boson mass with the CDF II detector

113. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

118. EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

119. 1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

120. 1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

126. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

131. High-precision measurement of the W boson mass with the CDF II detector

134. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis

135. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results

136. 74TiP Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC

137. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

138. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

145. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

146. 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L

147. 1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor

148. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Catalog

Books, media, physical & digital resources